newsfilter
← Earnings
Earnings Releases·

Evofem — Third Quarter 2026 Earnings Summary

  • Q3 2026 net sales declined to $4.6 million from $5.0 million in the prior year period, while net income turned positive at $0.9 million compared to a $1.7 million loss in Q3 2025.
  • Total operating expenses decreased to $3.9 million in Q3 2026 from $4.0 million in the prior year, though restricted cash fell to $0.3 million as of September 30, 2026.
  • PHEXX sales decreased due to inventory sell-through ahead of a price increase, while SOLOSEC unit sales rose and a second manufacturer was contracted to produce PHEXX.
  • Management attributes sales declines to a lack of dedicated growth capital since late 2022 but remains confident in long-term value pending targeted commercial investment.
  • Regulatory work continues for SOLOSEC in Uganda and the NIH-funded Phase 4 trial, while the company highlights risks including limited cash resources and going concern dependence on new capital.
Company
EVOFEM BIOSCIENCES INC
Sector
Healthcare
Industry
Biotechnology